Clinical trials: Ritonavir
HIV Infections
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
This is an open-label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized…
- Trial name
- NCT00056641
- Testing
- tipranavir, ritonavir, saquinavir
- Where
- 109 sites in United States, Australia and 11 more
- Volunteers
- 328 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Adult, Impaired Liver Function
Oral Docetaxel in Patients With Normal or Impaired Liver Function
This is an open label, single centre pharmacological and safety study to define the safety and pharmacokinetics of ModraDoc006/r in a weekly dosing schedule in patients with impaired liver function who might have benefit from a…
- Trial name
- NCT05084456
- Testing
- ModraDoc006/r
- Where
- Netherlands
- Sponsor
- Modra Pharmaceuticals
HIV Infection
Safety and Efficacy Study of Switching From Epzicom to Truvada
This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir…
- Trial name
- SWIFT (NCT00724711)
- Testing
- emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
- Where
- 80 sites in United States, Canada and 1 more
- Volunteers
- 312 people
- Sponsor
- Gilead Sciences
Hepatitis C
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
This study is a Phase I open label drug interaction study to evaluate the effect of omeprazole and ritonavir on GSK2336805.
- Trial name
- NCT01458054
- Testing
- Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study of the Pharmacokinetics of ASC09F in Healthy Subjects
The objective of this study is to evaluate the pharmacokinetic parameters of ASC09F in healthy subjects after multiple oral dosing.
- Trial name
- NCT04547894
- Testing
- ASC09F
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Infection, Human Immunodeficiency Virus
Single and Repeated Dose Escalation Study of GSK2838232
GSK2838232 is a Human Immunodeficiency Virus (HIV) maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy (ART).
- Trial name
- NCT02795754
- Testing
- GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
The purpose of this study is to evaluate clinical response and safety of a Kaletra containing antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.
- Trial name
- NCT00234975
- Testing
- Lopinavir/Ritonavir
- Where
- 11 sites in Puerto Rico
- Volunteers
- 86 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Healthy Participant
Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir
This is a drug-drug interaction study to assess the effects of a single dose of PF-07321332/ritonavir after multiple dose administrations of carbamazepine. Pharmacokinetic (PK) will be evaluated for PF-07321332 and ritonavir.
- Trial name
- NCT04962230
- Testing
- PF-07321332/ritonavir, Carbamazepine, PF 07321332/ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers
To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration.
- Trial name
- NCT02244190
- Testing
- Tipranavir, Ritonavir
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV
TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.
The purpose of the study is to determine the effect of steady-state concentrations of LPV, co-administered with a low dose of ritonavir, on the steady-state pharmacokinetics of TMC125 and to determine the effect of steady-state…
- Trial name
- NCT00767117
- Testing
- Etravirine; Lopinavir; Ritonavir
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give ABT-378/ritonavir combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected patients who previously have taken protease…
- Trial name
- NCT00004580
- Testing
- Lopinavir/Ritonavir, Nevirapine
- Where
- 10 sites in United States
- Sponsor
- Abbott
Human Immunodeficiency Virus-Infection
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.
- Trial name
- NCT01153269
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 8 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Abbott
Hepatic Impairment
A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers
This study was conducted to evaluate narlaprevir (NVR) pharmacokinetics (PK) after a single dose with or without ritonavir (RTV) in cirrhotic Child-Pugh class A patients without active HCV infection versus healthy subjects as…
- Trial name
- NCT03832426
- Testing
- Narlaprevir, Ritonavir
- Where
- 3 sites in Georgia, Russia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Chronic Hepatitis B
The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules
The Safety, Antiviral Activity, and pharmacokinetics of Morphothiadine Mesilate Capsules/Ritonavir Tablets in Patients with Chronic Hepatitis B
- Trial name
- NCT03638076
- Testing
- GLS4, RTV
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C Virus (HCV)
ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
This is a study to evaluate ABT 450/r/ABT-267 and ABT-333 in treatment-naïve and treatment-experienced Asian adults with subgenotype 1b chronic HCV without cirrhosis.
- Trial name
- NCT02517515
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir
- Volunteers
- 650 people
- Sponsor
- AbbVie
Antivirals/HIV
Drug Interaction Study
The purpose of this study is to evaluate the exposure of rifabutin (RIB) when administered with atazanavir and ritonavir (ATV/RTV)
- Trial name
- NCT00646776
- Testing
- Rifabutin, Rifabutin + Atazanavir + Ritonavir
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HCV, Hepatitis C Infection
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.
- Conditions
- HCV, Hepatitis C Infection, Genotype 4
- Trial name
- NCT02247401
- Testing
- 2 DAA, RBV
- Volunteers
- 160 people
- Sponsor
- AbbVie
Biological Availability, Healthy Participants
Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different FDC tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult…
- Trial name
- NCT05525910
- Testing
- Nirmatrelvir/ ritonavir, Nirmatrelvir/ritonavir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infection, Human Immunodeficiency Virus, HIV Infections
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
The primary purpose of this study is to study the safety and tolerability of a HIV drug and to evaluate a decrease of HIV-1 virus level in blood after treatments in HIV-1 infected patients
- Trial name
- NCT01803074
- Testing
- BMS-955176, Atazanavir, Ritonavir
- Where
- Germany
- Volunteers
- 107 people
- Sponsor
- ViiV Healthcare
HIV Infections
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the…
- Trial name
- NCT00530920
- Testing
- tipranavir, ritonavir
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim